

July 22, 2024

Nissan Chemical Announces Signing of License Agreement Regarding a selective SPR inhibitor NIP-322 for the Treatment of Pain with Maruho.

Nissan Chemical Corporation (Head office: Tokyo, Japan, President: Shinsuke Yagi) announces today the signing of a license agreement regarding NIP-322, a preclinical candidate identified by Nissan Chemical for the treatment of pain, with Maruho Co., Ltd. (Head office: Osaka, Japan, President and CEO: Atsushi Sugita).

Under the terms of the agreement, Nissan Chemical grants Maruho an exclusive license to research, develop and market NIP-322 in Japan, the US, Europe and Taiwan, and the right of first refusal in other countries, manufacturing and providing the active pharmaceutical ingredient. Nissan Chemical will receive an upfront payment, milestone payments based on the progress and royalties from Maruho.

NIP-322 is a selective inhibitor of sepiapterin reductase (SPR) which plays an important role in the biosynthesis of tetrahydrobiopterin related to the cause of pain. It is expected to manage chronic pain through a novel mechanism differently from the existing drugs.

Nissan Chemical will work on developing a novel analgesic with high safety and efficacy in collaboration with Maruho.

About Maruho Co., Ltd.

Maruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,566 employees (as of the end of September 2023), and net sales were approximately 85.71 billion yen in its fiscal year ended September 30, 2023. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile.

For more information, please visit <https://www.maruho.co.jp/english/>.

About Nissan Chemical Corporation

Nissan Chemical Corporation contributes to solving social issues providing products and services through four business areas – Performance materials, Agricultural chemicals, Chemicals, and Healthcare. We will acquire new technologies and accelerate growth in each business area by improving and combining core

technologies.

For more information, please visit www.nissanchem.co.jp/.

Contact information for inquiries on the above
Nissan Chemical Corporation Corporate Planning Department Planning Office, Public Relations Group E-mail : pr_cpd@nissanchem.co.jp